In summary, this study for the first time clarified the anticolorectal cancer role of BRU: BRU inhibits tumor growth and metastasis in vivo and in vitro by blocking the RhoA/ROCK1 signaling pathway-mediated EMT process. Here, ROCK1 is linked to neoplasm.